Citations

Clear

4207 citation(s) found for "Yu, Chen".

PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Yang, Yinhui , He, Yundong , Chen, Jiaxiang , Pan, Yunqian , Hinten, Michael, Karnes, R. Jeffrey , Westendorf, Jennifer J., Li, Benyi , Zhu, Runzhi , Xu, Wanhai , Kohli, Manish , Bai, Yang , Zhao, Yu , Ma, Linlin , Zhang, Jun , Westendorf, Jennifer J. , Huang, Haojie

Mayo Clinic

Clinical Cancer Research | November 22, 2017 | Volume: 24 | Issue: 4 | Pages: 834-846

10.1158/1078-0432.ccr-17-2006 | PMID 29167276 Get It

Abstract Purpose: Intratumoral androgen synthesis (IAS) is a key mechanism promoting androgen receptor (AR) reactivation and antiandrogen resistance in castration-resistant prostate cancer (CRPC). However, signaling pathways driving aberrant IAS remain poorly understood. Experimental Design: The effect of components of the AKT-RUNX2-osteocalcin (OCN)–GPRC6A–CREB signaling axis on expression of steroidogenesis genes CYP11A1 and CYP17A1 and testosterone level were examined in PTEN-null human prostate cancer cell lines. Pten knockout mice were used to examine the effect of Runx2 heterozygous deletion or abiraterone acetate (ABA), a prodrug of the CYP17A1 inhibitor abiraterone on Cyp11a1 and Cyp17a1 expression, testosterone level and tumor microenvironment (TME) remodeling in vivo. Results: We uncovered that activation of the AKT–RUNX2–OCN–GPRC6A–CREB signaling axis induced expression of CYP11A1 and CYP17A1 and testosterone production in PTEN-null prostate cancer cell lines in culture. Deletion of Runx2 in Pten homozygous knockout prostate tumors decreased Cyp11a1 and Cyp17a1 expression, testosterone level, and tumor growth in castrated mice. ABA treatment also inhibited testosterone synthesis and alleviated Pten loss-induced tumorigenesis in vivo. Pten deletion induced TME remodeling, but Runx2 heterozygous deletion or ABA treatment reversed the effect of Pten loss by decreasing expression of the collagenase Mmp9. Conclusions: Abnormal RUNX2 activation plays a pivotal role in PTEN loss-induced IAS and TME remodeling, suggesting that the identified signaling cascade represents a viable target for effective treatment of PTEN-null prostate cancer, including CRPC. Clin Cancer Res; 24(4); 834–46. ©2017 AACR.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Catalano, John, Belch, Andrew , Cavo, Michèle , Pinto, Antonello, Banos, Anne , Tiab, Mourad, Delforge, Michel , Cavenagh, Jamie, Lee, Je‐Jung , Chen, Christine , Oriol, Albert , Rubia, Javier de la , White, Darrell , Binder, Daniel, Moreau, Philippe , Perrot, Aurore , Arnulf, Bertrand , Qiu, Lugui , Roussel, Murielle , Boyle, Eileen M. , Manier, Salomon , Mohty, Mohamad , Avet‐Loiseau, Hervé , Leleu, Xavier , Ervin‐Haynes, Annette, Chen, Guang , Houck, Vanessa, Benboubker, Lotfi , Hulin, Cyrille , Pinto, Antonio , Moreau, Philippe , Perrot, Aurore , Boyle, Eileen M , Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Dispenzieri, Angela , Pinto, Antonello, Weisel, Katja C , Ludwig, Heinz , Bahlis, Nizar Jacques , Geraldes, Catarina , Lu, Jin Ping , Anderson, Kenneth C. , Attal, Michel , Qiu, Lugui , Roussel, Murielle , Pinto, Antonio , Oriol, Albert , Mohty, Mohamad

Mayo Clinic

Blood | November 17, 2017 | Volume: 131 | Issue: 3 | Pages: 301-310

10.1182/blood-2017-07-795047 | PMID 29150421 Get It

Key Points Rd continuous significantly extended OS compared with MPT and resulted in comparable OS to that with Rd18 in patients with multiple myeloma. Patients achieving complete or very good partial response with Rd benefited greatly from continuous vs fixed treatment in terms of PFS.
Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder
Amare, Azmeraw T. , Schubert, Klaus Oliver , Clark, Scott R. , Papiol, Sergi , Heilbronner, Urs , Degenhardt, Franziska , Tekola‐Ayele, Fasil , Hsu, Yi‐Hsiang , Shekhtman, Tatyana , Adli, Mazda , Akula, Nirmala , Akiyama, Kazufumi , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Bhattacharjee, Abesh Kumar, Benabarre, Antonio , Bengesser, Susanne , Birner, Armin , Brichant‐Petitjean, Clara, Cervantes, Pablo , Chen, Hsi‐Chung , Chillotti, Caterina , Cichon, Sven , Cruceanu, Cristiana , Czerski, Piotr M. , Dalkner, Nina , Zompo, Maria Del , Étain, Bruno , Falkai, Peter , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Fullerton, Janice M. , Gard, Sébastien, Grigoroiu‐Serbânescu, Maria , Grof, Paul , Hashimoto, Ryota , Jamain, Stéphane , Jiménez, Esther , Kahn, Jean‐Pierre, Kassem, Layla, Kuo, Po‐Hsiu , Kato, Tadafumi , Kittel‐Schneider, Sarah , Kliwicki, Sebastian , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Leckband, Susan G. , Tortorella, Alfonso , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , Novák, Tomáš , O’Donovan, Claire , Ozaki, Norio , Ösby, Urban, Pfennig, Andrea , Potash, James B. , Reif, Andreas , Reininghaus, Eva Z. , Schalling, Martin , Schofield, Peter R. , Schweizer, Barbara , Severino, Giovanni , Shilling, Paul D. , Shimoda, Katzutaka, Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Stopková, Pavla , Maj, Mario , Turecki, Gustavo , Vieta, Eduard , Volkert, Julia, Zandi, Peter P. , Bauer, Michael , Alda, Martin , McMahon, Francis J. , Etain, B , Vieta, E , Schofield, Peter R , Cichon, Sven , Nöthen, Markus M , Alda, Martin , Fullerton, Janice M , Hou, Liping , Backlund, Lena , Bellivier, Frank , Biernacka, Joanna M. , Dalkner, Nina , Dayer, Alexandre G. , DePaulo, J Raymond , Garnham, Julie , Goes, Fernando , Hauser, Joanna , Herms, Stefan , Hoffmann, Per , Hofmann, Andrea , Kelsoe, John R , König, Barbara , Kusumi, Ichiro , McElroy, Susan L. , Colom, Francesc , Monteleone, Palmiero , Nievergelt, Caroline M , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Squassina, Alessio , Witt, Stephanie H. , Wright, A. Jordan , Mitchell, Philip B , Rietschel, Marcella , Schulze, Thomas , Baune, Bernhard , Amare, Azmeraw , Papiol, Sergi , Heilbronner, Urs , Chen, Hsi-Chung , Cruceanu, Cristiana , Czerski, Piotr , Jamain, Stéphane , Grigoroiu-Serbanescu, Maria , Kuo, Po-Hsiu , Kittel-Schneider, Sarah , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Novak, Tomas , Reif, Andreas , Stopkova, Pavla , Turecki, Gustavo , McMahon, Francis , Arias, Bárbara , Hashimoto, Ryota , Ozaki, Norio , Schubert, Klaus Oliver , Kato, Tadafumi , Mitjans, Marina , Manchia, Mirko

Mayo Clinic

JAMA Psychiatry | November 15, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamapsychiatry.2017.3433 | PMID 29121268 Get It

Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Purnell, Jonathan Q. , Braffett, Barbara H. , Zinman, Bernard, Gubitosi‐Klug, Rose , Sivitz, William, Bantle, John P., Ziegler, Georgia, Cleary, Patricia A., Brunzell, John D. , Nathan, D.M., Zinman, B., Crofford, O., Genuth, S., Brown-Friday, J., Crandall, J., Engel, S., Martinez, H., Phillips, M., Reid, M., Shamoon, H., Sheindlin, J., Gubitosi-Klug, R., Mayer, L., Pendegast, S., Zegarra, H., Miller, D., Singerman, L., Smith-Brewer, S., Novak, M., Quin, J., Genuth, Saul, Palmert, M., Brown, E., McConnell, J., Pugsley, P., Crawford, P., Dahms, W., Gregory, N.S., Lackaye, M.E., Kiss, S., Chan, R., Orlin, A., Rubin, M., Brillon, D., Reppucci, V., Lee, T., Heinemann, M., Chang, S., Levy, B., Jovanovic, L., Richardson, M., Bosco, B., Dwoskin, A., Hanna, R., Barron, S., Campbell, R., Bhan, A., Krüger, D., Jones, J.K., Edwards, P.A., Bhan, A., Carey, J.D., Angus, E., Thomas, A., Galprin, A., McLellan, M., Whitehouse, F., Bergenstal, R., Johnson, M., Gunyou, K., Thomas, L., Laechelt, J., Hollander, P., Spencer, M., Kendall, D., Cuddihy, R., Callahan, P., List, S., Gott, J., Rude, N., Olson, B., Franz, M., Castle, G., Birk, R., Nelson, J., Freking, D., Gill, L., Mestrezat, W., Etzwiler, D., Morgan, K., Aiello, L.P., Golden, E., Arrigg, P., Asuquo, V., Beaser, R., Bestourous, L., Cavallerano, J., Cavicchi, R., Ganda, O., Hamdy, O., Kirby, R., Murtha, T., Schlossman, D., Shah, S., Sharuk, G., Silver, P., Silver, P., Stockman, M., Sun, J., Weimann, E., Wolpert, H., Aiello, L. M., Jacobson, A., Rand, L., Rosenzwieg, J., Nathan, D.M., Larkin, M.E., Christofi, M., Folino, K., Godine, J., Lou, P., Stevens, C., Anderson, E., Bode, H., Brink, S., Cornish, C., Cros, D., Delahanty, L., deManbey, A., Haggan, C., Lynch, J., McKitrick, C., Norman, D., Moore, D., Ong, M., Taylor, C., Zimbler, D., Crowell, S., Fritz, S., Hansen, K., Gauthier‐Kelly, C., Service, F. J., Ziegler, G., Barkmeier, A., Schmidt, L., French, B., Woodwick, R., Rizza, R., Schwenk, W. F., Haymond, M., Pach, J., Mortenson, J., Zimmerman, B., Lucas, A., Colligan, R., Luttrell, L., Lopes-Virella, M., Caulder, S., Pittman, C., Patel, N., Lee, K., Nutaitis, M., Fernandes, J., Hermayer, K., Kwon, S., Blevins, A., Parker, J., Colwell, J., Lee, D., Soule, J., Lindsey, P., Bracey, M., Farr, A., Elsing, S., Thompson, T., Selby, J., Lyons, T., Yacoub-Wasef, S., Szpiech, M., Wood, D., Mayfield, R., Molitch, M., Adelman, D., Colson, S., Jampol, L., Lyon, A., Gill, M., Strugula, Z., Kaminski, L., MIRZA, R., Simjanoski, E., Ryan, D., Johnson, C., Wallia, A., Ajroud-Driss, S., Astelford, P., Leloudes, N., Degillio, A., Schaefer, B., Mudaliar, S., Lorenzi, G., Goldbaum, M., Jones, K., Prince, M., Swenson, M., Grant, I., Reed, R., Lyon, R., Kolterman, O., Giotta, M, Clark, T., Friedenberg, G., Sivitz, W.I., Vittetoe, B., Kramer, J., Bayless, M., Zeitler, R., Schrott, H., Olson, N., Snetselaar, L., Hoffman, R., MacIndoe, J., Weingeist, T., Fountain, C., Miller, R., Johnsonbaugh, S., Patronas, M., Carney, M., Mendley, S., Salemi, P., Liss, R., Hebdon, M., Counts, D., Donner, T., Gordon, J., Hemady, R., Kowarski, A., Ostrowski, D., Steidl, S., Jones, B., Herman, W.H., Martin, C.L., Pop-Busui, R., Greene, D. A., Stevens, M.J., Burkhart, N., Sandford, T, Floyd, J., Bantle, J., Flaherty, N., Terry, J., Koozekanani, D., Montezuma, S., Wimmergren, N., Rogness, B., Mech, M., Strand, T., Olson, J., McKenzie, L., Kwong, C., Goetz, F., Warhol, R., Hainsworth, D., Goldstein, D., Hitt, S., Giangiacomo, J., Schade, D.S., Canady, J.L., Burge, M. R., Das, A., Avery, R.B., Ketai, L.H., Chapin, J.E., Schluter, M.L, Rich, J., Johannes, C., Hornbeck, D., Schutta, M., Bourne, P.A., Brucker, A., Braunstein, S., Schwartz, S., Maschak-Carey, B. J., Baker, L., Orchard, T., Cimino, L., Songer, T., Doft, B., Olson, S., Becker, D., Rubinstein, D., Bergren, R.L., Fruit, J., Hyre, R., Palmer, C., Silvers, N., Lobes, L., Rath, P. Paczan, Conrad, P. W., Yalamanchi, S., Wesche, J., Bratkowksi, M., Arslanian, S., Rinkoff, J., Warnicki, J., Curtin, D., Steinberg, D., Vagstad, G., Harris, R., Steranchak, L., Arch, J., Kelly, K., Ostrosaka, P., Guiliani, M., Good, M., Williams, T., Olsen, K., Campbell, A., Shipe, C., Conwit, R., Finegold, D., Zaucha, M., Drash, A., Morrison, A., Malone, J.I., Bernal, M.L., Pavan, P. R., Grove, N., Tanaka, E.A., McMillan, D., Vaccaro‐Kish, J., Babbione, L., Solc, H., DeClue, T.J., Dagogo-Jack, S., Wigley, C., Ricks, H., Kitabchi, A., Chaum, E., Murphy, M.B., Moser, S., Meyer, D., Iannacone, A., Yoser, S., Bryer‐Ash, M., Schüßler, S., Lambeth, H., Raskin, P., Strowig, S., Basco, M., Cercone, S., Zinman, B., Barnie, A., Devenyi, R., Mandelcorn, M., Brent, M., Rogers, S., Gordon, A., Bakshi, N., Perkins, B., Tuason, L., Perdikaris, F., Ehrlich, R., Daneman, D., Perlman, K., Ferguson, S., Palmer, J., Fahlstrom, R., Boer, I.H.de, Kinyoun, J., Ottingham, L. Van, Catton, S., Ginsberg, J., McDonald, C., Harth, J., Driscoll, M., Sheidow, T., Mahon, J., Canny, C., Nicolle, D., Colby, P., Dupre, J., Hramiak, I., Rodger, NW, Jenner, M., Smith, T., Brown, W., May, M., Hagan, J. Lipps, Agarwal, A., Adkins, T., Lorenz, R., Feman, S., Survant, L., White, N. H., Levandoski, L., Grand, G., Thomas, M., Joseph, D., Blinder, K., Shah, G., Burgess, D., Boniuk, I., Santiago, J., Tamborlane, W., Gatcomb, P., Stoessel, K., Ramos, P., Fong, K., Ossorio, P., Ahern, J., Meadema-Mayer, L., Beck, C., Farrell, K., Quin, J., Gaston, P., Trail, R., Lachin, J., Backlund, J., Bebu, I., Braffett, B., Diminick, L., Gao, X., Hsu, W., Klumpp, K., Trapani, Victoria R., Trapani, V., Cleary, P., McGee, P., Sun, W. , Villavicencio, S., Anderson, K., Dews, L., Younes, Naji , Rutledge, B., Chan, K., Rosenberg, D. , Petty, B., Determan, A., Kenny, D., Williams, C., Cowie, C., Siebert, C., Steffes, M., Arends, V., Bucksa, J., Nowicki, M., Chavers, B., O’Leary, D., Polák, J. (Jaroslav), Harrington, A., Funk, L., Crow, R., Gloeb, B., Thomas, S., O’Donnell, C., Soliman, EZ, Zhang, Z.M., Li, Y., Campbell, C., Keasler, L., Hensley, S., Hu, J., Barr, M., Taylor, T., Prineas, R., Feldman, E.L., Albers, J.W., Low, P., Sommer, C., Nickander, K., Speigelberg, T., Pfiefer, M., Schumer, M., Moran, M., Farquhar, J., Ryan, C., Sandstrom, D., Geckle, M., Cupelli, E., Thoma, F., Burzuk, B., Woodfill, T., Danis, R., Blodi, B., Lawrence, D., Wabers, H., Gangaputra, S., Neill, S., Burger, M., Dingledine, J., Gama, V., Sussman, R., Davis, M., Hubbard, L., Budoff, M., Darabian, S., Rezaeian, P., Wong, N., Fox, M., Oudiz, R., Kim, L., Detrano, R., Cruickshanks, K., Bainbridg, K., Lima, J., Bluemke, D., Turkbey, E., Geest, R. J. van der, Liu, C., Malayeri, A., Jain, A., Miao, C., Chahal, H., Jarboe, R., Nathan, D.M., Monnier, V., Sell, D., Strauch, C., Hazen, S., Pratt, A., Tang, W., Brunzell, J., Purnell, J., Purnell, J., Natarajan, R., Miao, F., Zhang, L., Chen, Z., Paterson, A., Boright, A., Bull, S., Sun, L., Scherer, S., Lyons, T.J., Jenkins, A., Klein, R., Virella, G., Jaffa, A., Carter, R., Stoner, J., Garvey, W.T., Lackland, D., Brabham, M., McGee, D., Zheng, D., Mayfield, R. K., Maynard, J., Wessells, H., Sarma, A., Dunn, R., Holt, S., Hotaling, J., Kim, C., Clemens, Q., McVary, Kevin T. , Cuddihy, Robert , Paterson, Andrew D. , Gubitosi-Klug, Rose A , Paterson, Andrew , Zinman, Bernard , Sivitz, William I. , Ziegler, G., Nathan, D.M., Engel, Samuel S. , Reid, M., Genuth, Saul, McConnell, J., Campbell, R., Carey, J.D., Dd, Etzwiler, Cavallerano, Jerry D. , Larkin, M.E., DeManbey, Andrea, Ajroud-Driss, S., Mudaliar, S., Herman, W.H., Pop-Busui, R., Mech, Michael, Schade, D.S., Schwartz, S., Becker, Dj., Arch, J., Shipe, C., Drash, A L, Pavan, P R , DeClue, Terry J., Raskin, P., Rogers, S., Boer, I.H. de, Dupre, J, Tamborlane, W., Gatcomb, P., Bebu, I., Cleary, P., McGee, P., Steffes, M., Arends, V., Bm, Chavers, Polak, J., Feldman, E. L., Nickander, K. K., Pfiefer, M., Dittz, Dalton , Virella, Gabriel, Mayfield, R. K., Brown, Jonathan D. , Cuddihy, Robert M

Mayo Clinic

Diabetes Care | November 15, 2017 | Volume: 40 | Issue: 12 | Pages: 1756-1762

10.2337/dc16-2523 | PMID 29138273 Get It

OBJECTIVE Intensive treatment (INT) of type 1 diabetes reduces the incidence of cardiovascular disease (CVD) events compared with conventional treatment (CONV), but it also results in more weight gain. Our objective was to examine whether excessive weight gain from INT of type 1 diabetes is independently associated with subsequent CVD events. RESEARCH DESIGN AND METHODS Quartiles (Q) of weight gain in 1,213 participants aged 18 years and older at enrollment in the Diabetes Control and Complications Trial (DCCT) were determined within randomized treatment groups (INT vs. CONV) using change in BMI from baseline to the closeout DCCT visits. Effects of this weight gain on CVD risk factors and outcomes during an additional 20 years of observational follow-up were then determined. RESULTS The Q4 INT group experienced greater proportional weight gain (median change in BMI, 6.08 kg/m2), increases in CVD risk factors, and need for medications for hypertension and lipids compared with the Q1–3 INT and comparable CONV groups. Over a mean of 26 years of follow-up, the numbers of major and total CVD events were not statistically different in Q4 compared with Q1–3 of either the INT or CONV group. By year 14, however, the incident CVD event curve became significantly higher in the Q4 INT group than in the Q1–3 INT groups (P = 0.024) and was similar to that for the CONV group. CONCLUSIONS For the first 13 years after DCCT, INT for type 1 diabetes reduced macrovascular events compared with CONV, even when excessive weight gain occurred. After this, total CVD events significantly increased in the Q4 INT group, becoming equivalent to those in the CONV group. Longer follow-up is needed to determine whether this trend continues and results in more major CVD events.
Nomenclature of Cutaneous Vasculitis
Sunderkötter, Cord , Zelger, Bernhard, Chen, Ko‐Ron , Requena, Luis , Piette, Warren W., Dutz, Jan , Lamprecht, Peter , Mahr, Alfred , Aberer, Elisabeth , Wetter, David A. , Kawana, Seiji, Françès, Camille, Jorizzo, Joseph L. , Watts, J. Richard, Metze, Dieter , Caproni, Marzia , Alpsoy, Erkan , Callen, Jeffrey P. , Falk, Ronald J. , Jennette, J. Charles , Mahr, Alfred , Carlson, J. Andrew , Werth, Victoria P. , Luqmani, Raashid Ahmed , Fiorentino, David Franklin , Merkel, Peter A. , Jennette, J Charles , Caproni, Marzia

Mayo Clinic

Arthritis & Rheumatology | November 14, 2017 | Volume: 70 | Issue: 2 | Pages: 171-184

10.1002/art.40375 | PMID 29136340 Get It

Objective To prepare a dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides ( CHCC 2012) to address vasculitides affecting the skin (D‐ CHCC ). The goal was to standardize the names and definitions for cutaneous vasculitis. Methods A nominal group technique with a facilitator was used to reach consensus on the D‐ CHCC nomenclature, using multiple face‐to‐face meetings, e‐mail discussions, and teleconferences. Results Standardized names, definitions, and descriptions were adopted for cutaneous components of systemic vasculitides (e.g., cutaneous IgA vasculitis as a component of systemic IgA vasculitis), skin‐limited variants of systemic vasculitides (e.g., skin‐limited IgA vasculitis, drug‐induced skin‐limited antineutrophil cytoplasmic antibody–associated vasculitis), and cutaneous single‐organ vasculitides that have no systemic counterparts (e.g., nodular vasculitis). Cutaneous vasculitides that were not included in the CHCC 2012 nomenclature were introduced. Conclusion Standardized names and definitions are a prerequisite for developing validated classification and diagnostic criteria for cutaneous vasculitis. Accurate identification of specifically defined variants of systemic and skin‐limited vasculitides requires knowledgeable integration of data from clinical, laboratory, and pathologic studies. This proposed nomenclature of vasculitides affecting the skin, the D‐ CHCC , provides a standard framework both for clinicians and for investigators.
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Hendrickson, Andrea E. Wahner , Menefee, Michael E., Hartmann, Lynn C. , Long, Harry J., Northfelt, Donald W. , Boakye‐Agyeman, Felix , Kayode, Olumide, Flatten, Karen S., Harrell, Maria I., Swisher, Elizabeth M. , Poirier, Guy G. , Satele, Daniel , Allred, Jake, Lensing, Janet L., Chen, Alice P. , Ji, Jiuping , Zang, Yiping , Erlichman, Charles , Haluska, Paul , Wahner Hendrickson, Andrea E, Reid, Joel M. , Boakye-Agyeman, Felix, Kaufmann, Scott H. , Swisher, Elizabeth M , Zang, Yiping

Mayo Clinic

Clinical Cancer Research | November 14, 2017 | Volume: 24 | Issue: 4 | Pages: 744-752

10.1158/1078-0432.ccr-17-1590 | PMID 29138343 Get It

Abstract Purpose: To determine the dose limiting toxicities (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of veliparib in combination with weekly topotecan in patients with solid tumors. Correlative studies were included to assess the impact of topotecan and veliparib on poly(ADP-ribose) levels in peripheral blood mononuclear cells, serum pharmacokinetics of both agents, and potential association of germline repair gene mutations with outcome. Experimental Design: Eligible patients had metastatic nonhematologic malignancies with measurable disease. Using a 3 + 3 design, patients were treated with veliparib orally twice daily on days 1–3, 8–10, and 15–17 and topotecan intravenously on days 2, 9, and 16 every 28 days. Tumor responses were assessed by RECIST. Results: Of 58 patients enrolled, 51 were evaluable for the primary endpoint. The MTD and RP2D was veliparib 300 mg twice daily on days 1–3, 8–10, and 15–17 along with topotecan 3 mg/m2 on days 2, 9, and 16 of a 28-day cycle. DLTs were grade 4 neutropenia lasting >5 days. The median number of cycles was 2 (1–26). The objective response rate was 10%, with 1 complete and 4 partial responses. Twenty-two patients (42%) had stable disease ranging from 4 to 26 cycles. Patients with germline BRCA1, BRCA2, or RAD51D mutations remained on study longer than those without homologous recombination repair (HRR) gene mutations (median 4 vs. 2 cycles). Conclusions: Weekly topotecan in combination with veliparib has a manageable safety profile and appears to warrant further investigation.
IL-33–Responsive Group 2 Innate Lymphoid Cells Are Regulated by Female Sex Hormones in the Uterus
Bartemes, Kathleen R. , Iijima, Koji, Drake, Li Y. , Kita, Hirohito , Chen, Chien-Chang, Drake, Li , Kita, H , Chen, Chien‐Chang

Mayo Clinic

The Journal of Immunology | November 13, 2017 | Volume: 200 | Issue: 1 | Pages: 229-236

10.4049/jimmunol.1602085 | PMID 29133293 Get It

Abstract Group 2 innate lymphoid cells (ILC2s) reside in multiple organs in the body, where they play roles in immunity, tissue homeostasis, and metabolic regulation. However, little is known about the regulatory mechanisms of ILC2s in different organs. Here, we identified ILC2s in the mouse uterus and found that they express cell surface molecules, including the IL-33 receptor, ST2, that are roughly comparable to those expressed by lung ILC2s. Both in vivo and in vitro treatment with IL-33 induced type 2 cytokine production in uterine ILC2s, suggesting that they respond to IL-33 in a manner similar to ILC2s in other organs. Importantly, uterine ILC2s were nearly absent in ovariectomized mice and were increased in wild-type mice by estrogen administration, whereas lung ILC2s were unaffected by both ovariectomy and estrogen administration. Likewise, a marked reduction in uterine ILC2s was observed in mice deficient in estrogen receptor α or estrogen receptor β. Furthermore, uterine ILC2s highly expressed estrogen receptor α, and in vitro culture of isolated uterine ILC2s with 17β-estradiol modified expression of a number of genes. Finally, an increased prevalence in neonatal mortality was observed in litters from dams lacking the IL-33 receptor, ST2. Taken together, our findings indicate that unlike lung IL2Cs, uterine ILC2s are regulated by female sex hormones, which may specialize them for specific physiological functions.
Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)
Darke, Amy K. , Zirpoli, Gary , Davis, Warren , Ondracek, Rochelle Payne , Bshara, Wiam , Omilian, Angela R. , Kratzke, Robert A. , Reid, Mary E. , Molina, Julian R. , Chen, Yuhchyau , MacRae, Robert M. , Gandara, David R. , Kelly, Karen , Santella, Regina M. , Albain, Kathy S. , Kelly, Karen , Cheng, Ting‐Yuan David , Redman, Mary W. , Kolesar, Jill , Moon, James , Mack, Philip C. , Ambrosone, Christine B. , Zirpoli, Gary , Gandara, David

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 13, 2017 | Volume: 110 | Issue: 7 | Pages: 734-742

10.1093/jnci/djx260 | PMID 29346580 Get It

A simple and effective crepe bandage splinting method to decrease tension after large superficial circumflex iliac artery perforator (SCIP) flap donor site closure
Ciudad, Pedro , Vijayan, Roshan , Pafitanis, Georgios , Pont, Luis Parra , Kaya, Burak , Agko, Mouchammed , Manrique, Oscar J. , Chang, Wei‐Ling , Parra Pont, Luis , Mouchammed, Agko , Chen, Hung‐Chi

Mayo Clinic

Microsurgery | November 13, 2017 | Volume: 38 | Issue: 2 | Pages: 230-231

10.1002/micr.30267 | PMID 29131382 Get It

Dying in the Hospital: Perspectives of family members
Dose, Ann Marie , Carey, Elise C. , Rhudy, Lori M. , Frimannsdottir, Katrin R., Ottenberg, Abigale L., Koenig, Barbara A. , Chiu, Yi‐Chen

Mayo Clinic

Journal of Palliative Care | November 13, 2017 | Volume: 31 | Issue: 1 | Pages: 13-20

10.1177/082585971503100103 | PMID 26399086 Get It

Background Although most patients express a preference to die at home, many (over 30 percent) still die in hospital. This study's purpose was to explore the experience of hospital death from the perspective of patients’ family members. Methods Interviews were conducted with family members of patients who had died at hospitals affiliated with a large tertiary referral centre in the United States. Content analysis was used to analyze findings. Findings We interviewed 30 family members by phone. Themes were arranged by time frame: before death, time of death, and after death. Conclusion Families do not interpret clinical cues leading up to death in the same way healthcare providers do; families need clear and direct explanations from providers. Clinicians should assess patient and family understandings of prognosis and communicate clearly and directly. Family members value being with their loved one at the time of death, and they value spending time with the body after death; this should be facilitated in clinical practice.